Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108,074,661
-
Total 13F shares
-
71,014,841
-
Share change
-
-501,375
-
Total reported value
-
$736,442,996
-
Put/Call ratio
-
121%
-
Price per share
-
$10.37
-
Number of holders
-
131
-
Value change
-
+$5,835,766
-
Number of buys
-
65
-
Number of sells
-
67
Institutional Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q2 2023
As of 30 Jun 2023,
Aclaris Therapeutics, Inc. - Common Stock (ACRS) was held by
131 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
71,014,841 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., RA CAPITAL MANAGEMENT, L.P., Rock Springs Capital Management LP, Bain Capital Life Sciences Investors, LLC, BVF INC/IL, VANGUARD GROUP INC, BRAIDWELL LP, Foresite Capital Management IV, LLC, and CITADEL ADVISORS LLC.
This page lists
131
institutional shareholders reporting positions in this security
for the Q2 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.